Headlines about Flexion Therapeutics (NASDAQ:FLXN) have trended somewhat negative on Friday, AlphaOne Sentiment Analysis reports. AlphaOne, a service of Accern, identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flexion Therapeutics earned a media sentiment score of -0.12 on AlphaOne’s scale. AlphaOne also assigned media stories about the specialty pharmaceutical company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Alpha One’s rankings:

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Shares of Flexion Therapeutics (NASDAQ:FLXN) traded up 0.18% during trading on Friday, reaching $17.00. The company had a trading volume of 127,417 shares. The firm has a 50-day moving average of $18.38 and a 200-day moving average of $20.36. The company’s market cap is $539.87 million. Flexion Therapeutics has a 12-month low of $13.20 and a 12-month high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.02. On average, equities research analysts anticipate that Flexion Therapeutics will post ($3.72) EPS for the current year.

Several research firms recently commented on FLXN. Wells Fargo & Company reiterated an “outperform” rating and issued a $30.00 target price on shares of Flexion Therapeutics in a research note on Saturday, March 25th. Royal Bank of Canada set a $44.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a research report on Sunday, March 26th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $34.00 target price (down previously from $37.00) on shares of Flexion Therapeutics in a research report on Tuesday, March 14th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $30.00 target price on shares of Flexion Therapeutics in a research report on Saturday, March 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 target price on shares of Flexion Therapeutics in a research report on Monday, May 15th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.60.

TRADEMARK VIOLATION WARNING: “Flexion Therapeutics (FLXN) Given Coverage Optimism Score of -0.12” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/06/16/flexion-therapeutics-flxn-earns-coverage-optimism-score-of-0-12-updated.html.

In related news, insider Neil Bodick sold 5,000 shares of the stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $28.23, for a total transaction of $141,150.00. Following the sale, the insider now owns 46,137 shares in the company, valued at approximately $1,302,447.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Frederick W. Driscoll sold 3,000 shares of the stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $23.00, for a total transaction of $69,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,777 shares of the company’s stock, valued at approximately $247,871. The disclosure for this sale can be found here. Company insiders own 18.00% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.